Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
October 04, 2024 01:00 ET
|
Molecular Partners
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40)...
LGI Homes Reports September and Third Quarter 2024 Home Closings and Announces Date for Third Quarter Earnings Conference Call
October 03, 2024 18:01 ET
|
LGI Homes, Inc.
THE WOODLANDS, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 579 homes in September 2024, a 7.2% year-over-year increase, resulting in a total of...
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024 18:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other...
Texas Capital Bancshares, Inc. Announces Date for Q3 2024 Operating Results
October 03, 2024 17:00 ET
|
Texas Capital Bancshares, Inc.
DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the...
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
October 03, 2024 16:45 ET
|
Onconetix, Inc.
CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the...
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
October 03, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus2+ study of its UX701 gene therapy has demonstrated...
Envoy Technologies Inc. Launches Turnkey, On-Demand Luxury Lucid EV Sharing as an Amenity
October 03, 2024 16:25 ET
|
Blink Charging Co.
New Lucid Air Tourings Now Available for Car Share Opportunities Los Angeles, CA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Envoy Technologies Inc. (“Envoy”), a Blink Charging Co. entity and leading...
HomeTrust Bank Committed to Serving Local Communities Following Hurricane Helene
October 03, 2024 16:18 ET
|
HomeTrust Bancshares, Inc.
ASHEVILLE, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- While the full impact of Hurricane Helene and its aftermath, including catastrophic rain and flooding, is still unknown, relief efforts continue,...
Uniti Group Inc. To Report Third Quarter 2024 Financial Results and Host Conference Call
October 03, 2024 16:15 ET
|
Uniti Group Inc.
LITTLE ROCK, Ark., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that it will report its third quarter 2024 financial results prior to the opening of...
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 03, 2024 16:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...